Articles dans des revues avec comité de lecture (33)
  1. 1. Torcida Sedano, N., Casalino, G., Bondue, A., Jodaitis, L., Vanden Eynden, F., & Roufosse, F. (2023). Case report: Serious unexpected vascular events in two patients with lymphocytic variant hypereosinophilic syndrome. Frontiers in Cardiovascular Medicine.
  2. 2. Macera, F., Dewachter, C., Stefanidis, C., Vanden Eynden, F., Bondue, A., Vachiery, J.-L., & Roussoulieres, A. (2023). Lung diffusion capacity correlates with pre-implant pulmonary hypertension and predicts outcome after LVAD implantation. ESC Heart Failure, 10(2), 1043-1053. doi:10.1002/ehf2.14256
  3. 3. Macera, F., Dewachter, C., Stefanidis, C., Vanden Eynden, F., Bondue, A., Vachiery, J.-L., & Roussoulieres, A. (2023). Lung diffusion capacity correlates with pre‐implant pulmonary hypertension and predicts outcome after LVAD implantation. ESC Heart Failure, 10(2), 1043-1053. doi:10.1002/ehf2.14256
  4. 4. Valente, F., Stefanidis, C., Vachiery, J.-L., Dewachter, C., Engelman, E., Vanden Eynden, F., & Roussoulieres, A. (2023). A novel metrics to predict right heart failure after left ventricular assist device implantation. Journal of artificial organs, 26(1), 24-35. doi:10.1007/s10047-022-01334-3
  5. 5. El Oumeiri, B. G., Dewachter, L., Van De Borne, P., Hubesch, G., Melot, C., Jespers, P., Stefanidis, C., McEntee, K., & Vanden Eynden, F. (2023). Altered Left Ventricular Rat Gene Expression Induced by the Myosin Activator Omecamtiv Mecarbil. Genes, 14(1). doi:10.3390/genes14010122
  6. 6. El Oumeiri, B. G., Van De Borne, P., Hubesch, G., Jespers, P., Dewachter, L., Stefanidis, C., McEntee, K., & Vanden Eynden, F. (2022). Detection of soluble suppression of tumorigenicity 2 and N-terminal B-type natriuretic peptide in a rat model of aortic regurgitation: differential responses to omecamtiv mecarbil. Journal of basic & clinical physiology & pharmacology, 33(6), 743-750. doi:10.1515/jbcpp-2022-0215
  7. 7. El Oumeiri, B. G., Van De Borne, P., Hubesch, G., Herpain, A., Annoni, F., Jespers, P., Stefanidis, C., Mc Entee, K., & Vanden Eynden, F. (2021). The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation. Physiological Reports, 9(16), e14988. doi:10.14814/phy2.14988
  8. 8. Coeckelenbergh, S., Valente, F., Mortier, J., Engelman, E., Roussoulieres, A., El Oumeiri, B. G., Antoine, M., Van Obbergh, L., Taccone, F., Vanden Eynden, F., & Stefanidis, C. (2021). Long-Term Outcome After Venoarterial Extracorporeal Membrane Oxygenation as Bridge to Left Ventricular Assist Device Preceding Heart Transplantation. Journal of cardiothoracic and vascular anesthesia. doi:10.1053/j.jvca.2021.06.035
  9. 9. Vanden Eynden, F., Segers, P., Bové, T., De Somer, F., El Oumeiri, B. G., & Van Nooten, G. (2019). Use of a right ventricular continuous flow pump to validate the distensible model of the pulmonary vasculature. Physiological Research, 68(2), 233-243. doi:10.33549/physiolres.933894
  10. 10. Joosten, A., Boudart, C., Vincent, J. L., Vanden Eynden, F., Barvais, L., Van Obbergh, L., Rinehart, J., & Desebbe, O. (2019). Ability of a New Smartphone Pulse Pressure Variation and Cardiac Output Application to Predict Fluid Responsiveness in Patients Undergoing Cardiac Surgery. Anesthesia and analgesia, 128(6), 1145-1151. doi:10.1213/ANE.0000000000003652
  11. 11. Oumeiri, B. E., McEntee, K., Annoni, F., Herpain, A., Vanden Eynden, F., Jespers, P., Van Nooten, G., & Van De Borne, P. (2018). Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats. BMC cardiovascular disorders, 18(1), 99. doi:10.1186/s12872-018-0831-3
  12. 12. Nguyen, T., Antoine, M., Vanden Eynden, F., Van Nooten, G., & El Oumeiri, B. G. (2018). A bullet through the aortic arch. Acta cardiologica, 73(3), 303-304. doi:10.1080/00015385.2017.1366401
    13. << Précédent 1 2 3 Suivant >>